4D Molecular Therapeutics (FDMT) Competitors $6.69 -0.11 (-1.62%) Closing price 04:00 PM EasternExtended Trading$6.72 +0.03 (+0.45%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. NUVB, WVE, ETNB, TLRY, PGEN, RCUS, NTLA, GPCR, XERS, and ABCLShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Nuvation Bio (NUVB), WAVE Life Sciences (WVE), 89BIO (ETNB), Tilray Brands (TLRY), Precigen (PGEN), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Structure Therapeutics (GPCR), Xeris Biopharma (XERS), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Its Competitors Nuvation Bio WAVE Life Sciences 89BIO Tilray Brands Precigen Arcus Biosciences Intellia Therapeutics Structure Therapeutics Xeris Biopharma AbCellera Biologics Nuvation Bio (NYSE:NUVB) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Does the media prefer NUVB or FDMT? In the previous week, Nuvation Bio and Nuvation Bio both had 5 articles in the media. Nuvation Bio's average media sentiment score of 1.00 beat 4D Molecular Therapeutics' score of 0.85 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, NUVB or FDMT? Nuvation Bio has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the S&P 500. Do institutionals & insiders have more ownership in NUVB or FDMT? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate NUVB or FDMT? Nuvation Bio currently has a consensus target price of $7.50, indicating a potential upside of 129.36%. 4D Molecular Therapeutics has a consensus target price of $30.40, indicating a potential upside of 354.41%. Given 4D Molecular Therapeutics' higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.174D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 Is NUVB or FDMT more profitable? Nuvation Bio has a net margin of -1,413.43% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-1,413.43% -46.14% -36.04% 4D Molecular Therapeutics -594,375.81%-40.15%-36.43% Which has preferable valuation and earnings, NUVB or FDMT? 4D Molecular Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M142.21-$567.94M-$0.63-5.194D Molecular Therapeutics$40K7,810.58-$160.87M-$3.53-1.90 SummaryNuvation Bio and 4D Molecular Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$317.58M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-1.9023.4975.8626.51Price / Sales7,810.58672.77528.74123.58Price / CashN/A169.4937.1760.46Price / Book0.615.3312.796.29Net Income-$160.87M$32.95M$3.28B$270.51M7 Day Performance-4.02%-0.44%0.22%2.15%1 Month Performance-7.85%3.91%4.61%6.35%1 Year Performance-59.41%-3.07%68.33%25.48% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.4484 of 5 stars$6.69-1.6%$30.40+354.4%-58.2%$317.58M$40K-1.90120Analyst ForecastNUVBNuvation Bio2.697 of 5 stars$3.48-10.9%$7.50+115.8%+3.0%$1.33B$7.87M-5.5260Gap DownHigh Trading VolumeWVEWAVE Life Sciences4.3173 of 5 stars$7.58-8.6%$20.33+168.2%+18.9%$1.32B$108.30M-8.42240Positive NewsETNB89BIO2.6328 of 5 stars$8.57-3.4%$28.00+226.7%-5.4%$1.32BN/A-2.3740Positive NewsAnalyst ForecastTLRYTilray Brands3.0083 of 5 stars$1.12-5.9%$1.94+73.0%-32.2%$1.31B$821.31M-0.482,842Positive NewsPGENPrecigen4.5534 of 5 stars$4.16-4.6%$8.25+98.3%+241.9%$1.30B$4.34M-9.90190Positive NewsRCUSArcus Biosciences1.867 of 5 stars$11.43-6.3%$21.14+85.0%-35.5%$1.30B$258M-3.60500Positive NewsNTLAIntellia Therapeutics4.4501 of 5 stars$11.84-1.8%$29.05+145.4%-47.6%$1.29B$57.88M-2.52600GPCRStructure Therapeutics3.4731 of 5 stars$20.86-5.5%$75.71+263.0%-50.5%$1.27BN/A-19.87136Positive NewsXERSXeris Biopharma2.7861 of 5 stars$7.77-1.0%$7.08-8.8%+155.6%$1.27B$203.07M-37.00290Positive NewsABCLAbCellera Biologics2.6454 of 5 stars$4.17-1.2%$8.00+91.8%+58.2%$1.26B$28.83M-7.58500News Coverage Related Companies and Tools Related Companies NUVB Alternatives WVE Alternatives ETNB Alternatives TLRY Alternatives PGEN Alternatives RCUS Alternatives NTLA Alternatives GPCR Alternatives XERS Alternatives ABCL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
